Loading company…
SFA Therapeutics develops biosynthetic compounds for inflammatory diseases and cancers.
SFA Therapeutics develops compounds that target disease-specific pathways for conditions including autoimmune diseases and cancers. Its lead program, SFA-002, is in a Phase 1b clinical trial for psoriasis. Founded in 2016, the company is based in Jenkintown, US. In November 2023, it raised USD 4.00 mn in Seed funding from investors including Acequia Capital and Ben Franklin Technology Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in